Developer docs
API playgroundTry for free, no card

Search company profiles

All G

Full company profile

uuid0000nkd

Namestring
All G
Legal namestring
All G Co Holdings Pty Limited
Websiteurl
allg.com
Company typeenum
Private
Founded yearint
2021
Descriptiontext

All G is an Australian biotechnology company founded in 2021 and headquartered in Sydney that develops and produces bio-identical milk proteins using precision fermentation technology. The company's core technical platform programs food-grade yeast microorganisms with DNA instructions to ferment high-value milk proteins, which are then purified through downstream processing and characterized using HPLC, LC-MS, and other analytical methods. Its product portfolio centres on LFX™ Bovine Lactoferrin — a >95% purity precision-fermented lactoferrin claimed to have higher iron-binding capacity and antioxidant activity than native bovine lactoferrin — alongside Human Lactoferrin, Micellar Caseins, and a broader Human Milk Proteins pipeline targeting breast-milk-equivalent infant formulations.

The company operates a B2B ingredient supply model, selling lactoferrin and human milk proteins to global enterprise customers in infant formula, dietary supplements, personal care, and functional foods and beverages. Pricing is quote-based and not publicly disclosed. All G supports customers with technical expertise, regulatory documentation, clinical trial data, and claims dossiers to enable product development and market entry across North America, Europe, Asia-Pacific, and China. Manufacturing at commercial scale is executed through a joint venture with Armor Protéines (Savencia Group) established December 2025, with additional pilot scale infrastructure via Doehler Ventures in Germany. Sales-led and channel-partner GTM motions are used in parallel.

The company has secured meaningful regulatory milestones that anchor its commercial positioning: world's first China CSAR approval for recombinant bovine lactoferrin (November 2024), US FDA self-affirmed GRAS status (late 2024), and an FDA 'no questions' letter (April 2026). These approvals in the two largest lactoferrin markets create a first-mover regulatory advantage. All G has raised over $56M USD across multiple funding rounds, with cumulative support from Agronomics Limited, CEFC, W23 (Woolworths), New Agrarian Company, Ellerston Capital, Doehler Ventures, and Triplestar. Commercial-scale production commenced in 2026, marking the transition from R&D to revenue-generating operations.

Short descriptiontext

All G is an Australian biotechnology company that uses precision fermentation to produce bio-identical milk proteins, including LFX™ bovine lactoferrin, human lactoferrin, micellar caseins, and human milk proteins. It supplies these ingredients to global infant formula, dietary supplement, personal care, and functional food manufacturers.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSydney, Australia
HQ citystring
Sydney
HQ countrystring
Australia
HQ regionstring
Oceania
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
precision fermentation proteins, lactoferrin ingredient supply, milk protein biotechnology, infant formula ingredients, human milk proteins
Industry4 codes
PRIMARYAFAHAJAJ
Precision-Fermentation Dairy Analogues Processing (Animal-Free Whey/Casein Products)
Agriculture & Food Production/Dairy Processing/Dairy Alternatives Processing (Plant-Based “Milk”, Yogurt & Cheese Analogues)
SECONDARYAFAKAKAF
Whey, Casein & Milk Protein Ingredient Manufacturing
SECONDARYAFAKAKAJ
Infant Formula & Specialized Dairy Nutrition Manufacturing
SECONDARYAFAJAHAC
Dairy Protein Ingredients (Whey, Casein/Caseinates, Milk Protein Concentrates/Isolates)
Agriculture & Food Production/Food Ingredients & Additives/Proteins & Protein Ingredients (Plant/Animal Proteins, Protein Isolates/Concentrates)
NAICS code1 code
  • Dairy Product Manufacturing3115
SIC code1 code
  • Dairy Products2020
Product category
Precision Fermentation Protein Ingredients
Social media profiles1 record
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model2 records
1Ingredient Sales — Lactoferrin and Milk Proteins
TypeTransaction Fee
Description

All G generates revenue through the sale of precision-fermented lactoferrin ingredients (LFX™) to manufacturers of functional foods, beverages, dietary supplements, personal care products, and infant formula. The company has received regulatory approvals in the US (FDA 'no questions' letter / GRAS) and China (CSAR), enabling commercial ingredient sales. Revenue-generating phase began in 2026 following commercial-scale production commencement.

allg.com
2Technical and Regulatory Services
TypeProfessional Services
Description

All G supports partners and customers with regulatory documentation, clinical trial data, claims dossiers, ingredient data, and technical expertise across global markets including dietary supplement, infant formula, and personal care. This supports customer product development and market entry.

allg.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1LFX™
Description

Precision-fermented bovine lactoferrin ingredient with >95% purity, bio-equivalent to animal-based lactoferrin.

allg.com
Core offering1 text field

All G develops and supplies high-purity bioactive milk proteins—including LFX™ bovine lactoferrin, human lactoferrin, micellar caseins, and human milk proteins—manufactured via precision fermentation of food-grade yeast. These protein ingredients are sold B2B to global manufacturers of infant formula, dietary supplements, functional foods/beverages, and personal care products, with bundled technical, regulatory, and clinical support. Commercial-scale production commenced in 2026 through a joint venture with Armor Protéines (Savencia Group).

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • Lactoferrin supplementation was associated with reduced systemic inflammation, improvements in immune function, and a lower incidence of respiratory tract infections in infants and children (meta-analysis of clinical trials)
+4 more records
Product overview1 text field

All G is an Australian biotechnology company that develops high-value human and bovine milk proteins through precision fermentation. The core product portfolio includes LFX™ Bovine Lactoferrin as the lead commercial product, along with Human Lactoferrin, Micellar Caseins, and Human Milk Proteins. The company also produced Love BUDS Burgers as its first consumer product. All products are produced using precision fermentation technology where microbes are programmed with DNA instructions and grown in fermentation tanks to produce bio-identical proteins. The product pipeline targets applications across infant formula, dietary supplements, personal care, and functional foods.

Product and service5 records
1LFX™ Bovine Lactoferrin
CategoryPrecision Fermentation Protein Ingredient
Description

Precision-fermented bovine lactoferrin ingredient produced via microbial fermentation of food-grade yeast, offering >95% purity, bio-equivalent activity to animal-based lactoferrin, higher iron-binding capacity, and higher antioxidant activity. Designed for use in functional foods, beverages, dietary supplements, and personal care formulations by global manufacturers.

2Human Lactoferrin
CategoryPrecision Fermentation Protein Ingredient
Description

Precision-fermented human lactoferrin protein produced via microbial fermentation. Adapted specifically to human biology, binding and delivering iron with high bioavailability. Naturally occurring in saliva, tears, and protective mucosal fluids. Designed for infant formula, dietary supplements, and advanced nutrition applications.

3Micellar Caseins
CategoryPrecision Fermentation Protein Ingredient
Description

Precision-fermented micellar casein proteins that self-assemble into microscopic spheres with calcium and phosphate, mimicking the natural micellar structure found in milk. All G has filed patents covering stable casein micelle production from single casein protein types. Designed for infant formula and nutritional applications.

4Human Milk Proteins
CategoryPrecision Fermentation Protein Ingredient
Description

Precision-fermented human milk proteins including human casein micelles and other breast milk proteins for infant formula and nutritional applications, developed to more closely align with the composition and function of human breast milk. Includes patented infant formulations containing five major human breast milk proteins.

5Love BUDS Burgers
CategoryPlant-Based Consumer Food Product
Description

Plant-based burger product developed using precision fermentation technology, launched as All G's first commercial product in Australian supermarkets.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-12-18
Description

All G formed a strategic joint venture with French lactoferrin producer Armor Protéines (owned by dairy major Savencia) to produce and commercialize bovine lactoferrin and human milk proteins at global scale. The JV combines All G's precision fermentation technology with Armor Protéines' established manufacturing infrastructure, supporting All G's first product launch of recombinant lactoferrin in 2026.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-01-01
Description

All G partnered with Doehler Ventures to establish a dedicated pilot facility in Germany supporting scale-up of precision fermentation production. Doehler Ventures also participated as an investor in All G's $10M convertible note fundraise in December 2025.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2021-09-06
Description

All G partnered with the University of Sydney for research collaboration as part of its founding strategy in 2021. The partnership supports the development of alternative proteins through academic research and expertise.

Strategic tierCoreTypeTechnology or Integration
Description

All G is scaling up lactoferrin production through partnerships with the University of Queensland's FaBA (Food and Beverage Accelerator), which supports advanced food and biotechnology manufacturing capabilities.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

US-based precision fermentation company developing recombinant human lactoferrin and other bioactive proteins for infant formula and supplements — the closest direct competitor to All G's LFX™ product line.

TypeDirect peer
Description

US precision fermentation leader producing animal-free whey protein for dairy applications; a broad platform competitor using similar microbial fermentation technology targeting B2B food and nutrition customers.

TypeDirect peer
Description

Israel-based precision fermentation company producing animal-free whey and casein proteins for dairy and infant nutrition — directly comparable technology platform and end-markets to All G.

TypeDirect peer
Description

Singapore/US precision fermentation company producing recombinant lactoferrin and other milk proteins using similar microbial host technology — direct overlap with All G's lactoferrin focus.

TypeDirect peer
Description

Israel-based precision fermentation startup producing animal-free casein and whey proteins for dairy alternatives, applying analogous fermentation approaches for B2B dairy ingredient customers.

TypeDirect peer
Description

Belgium-based precision fermentation company producing animal-free casein proteins for cheese applications — comparable microbial fermentation platform targeting dairy protein markets.

TypeDirect peer
Description

Germany-based precision fermentation company producing animal-free cheese proteins using microbial fermentation — comparable technology and European market overlap with All G's German pilot facility via Doehler.

TypeEmerging player
Description

Netherlands-based precision fermentation startup backed by DSM-Firmenich developing animal-free dairy proteins including lactoferrin — emerging competitor with corporate backing targeting overlapping B2B ingredient customers.

9Bon Vivant
TypeEmerging player
Description

France-based precision fermentation company producing animal-free whey proteins for dairy applications — emerging competitor with overlap in European precision-fermented dairy protein markets.

TypeOthers
Description

French lactoferrin producer and All G's JV partner under Savencia Group — comparable as the leading animal-derived lactoferrin incumbent, with JV relationship creating both partnership and competitive dynamics for All G.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance4 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors13 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

All G

Precision Fermentation Protein Ingredientsallg.com

All G is an Australian biotechnology company that uses precision fermentation to produce bio-identical milk proteins, including LFX™ bovine lactoferrin, human lactoferrin, micellar caseins, and human milk proteins. It supplies these ingredients to global infant formula, dietary supplement, personal care, and functional food manufacturers.

What All G does

All G is an Australian biotechnology company founded in 2021 and headquartered in Sydney that develops and produces bio-identical milk proteins using precision fermentation technology. The company's core technical platform programs food-grade yeast microorganisms with DNA instructions to ferment high-value milk proteins, which are then purified through downstream processing and characterized using HPLC, LC-MS, and other analytical methods. Its product portfolio centres on LFX™ Bovine Lactoferrin — a >95% purity precision-fermented lactoferrin claimed to have higher iron-binding capacity and antioxidant activity than native bovine lactoferrin — alongside Human Lactoferrin, Micellar Caseins, and a broader Human Milk Proteins pipeline targeting breast-milk-equivalent infant formulations.

The company operates a B2B ingredient supply model, selling lactoferrin and human milk proteins to global enterprise customers in infant formula, dietary supplements, personal care, and functional foods and beverages. Pricing is quote-based and not publicly disclosed. All G supports customers with technical expertise, regulatory documentation, clinical trial data, and claims dossiers to enable product development and market entry across North America, Europe, Asia-Pacific, and China. Manufacturing at commercial scale is executed through a joint venture with Armor Protéines (Savencia Group) established December 2025, with additional pilot scale infrastructure via Doehler Ventures in Germany. Sales-led and channel-partner GTM motions are used in parallel.

The company has secured meaningful regulatory milestones that anchor its commercial positioning: world's first China CSAR approval for recombinant bovine lactoferrin (November 2024), US FDA self-affirmed GRAS status (late 2024), and an FDA 'no questions' letter (April 2026). These approvals in the two largest lactoferrin markets create a first-mover regulatory advantage. All G has raised over $56M USD across multiple funding rounds, with cumulative support from Agronomics Limited, CEFC, W23 (Woolworths), New Agrarian Company, Ellerston Capital, Doehler Ventures, and Triplestar. Commercial-scale production commenced in 2026, marking the transition from R&D to revenue-generating operations.

All G firmographics

Firmographics
Name
All G
Legal name
All G Co Holdings Pty Limited
Website
https://allg.com
Company type
Private
Founded year
2021
Operating status
Operating
Headcount range
11–50 employees
Short description
All G is an Australian biotechnology company that uses precision fermentation to produce bio-identical milk proteins, including LFX™ bovine lactoferrin, human lactoferrin, micellar caseins, and human milk proteins. It supplies these ingredients to global infant formula, dietary supplement, personal care, and functional food manufacturers.
Ownership category
akta.pro rank

All G industry classification

Industry
Product category
Precision Fermentation Protein Ingredients
NAICS
Dairy Product Manufacturing (3115)
SIC
Dairy Products (2020)
akta.pro industry
PRIMARYAFAHAJAJ
Precision-Fermentation Dairy Analogues Processing (Animal-Free Whey/Casein Products)
Agriculture & Food Production/Dairy Processing/Dairy Alternatives Processing (Plant-Based “Milk”, Yogurt & Cheese Analogues)
SECONDARYAFAKAKAF
Whey, Casein & Milk Protein Ingredient Manufacturing
SECONDARYAFAKAKAJ
Infant Formula & Specialized Dairy Nutrition Manufacturing
SECONDARYAFAJAHAC
Dairy Protein Ingredients (Whey, Casein/Caseinates, Milk Protein Concentrates/Isolates)
Agriculture & Food Production/Food Ingredients & Additives/Proteins & Protein Ingredients (Plant/Animal Proteins, Protein Isolates/Concentrates)

Keywords

  • Precision fermentation proteins
  • Lactoferrin ingredient supply
  • Milk protein biotechnology
  • Infant formula ingredients
  • Human milk proteins

Where All G is headquartered

Location

Headquarters

HQ city
Sydney
HQ country
Australia
HQ region
Oceania

Offices1 record

Markets served

All G business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales

Revenue model

  1. Ingredient Sales — Lactoferrin and Milk Proteins: All G generates revenue through the sale of precision-fermented lactoferrin ingredients (LFX™) to manufacturers of functional foods, beverages, dietary supplements, personal care products, and infant formula. The company has received regulatory approvals in the US (FDA 'no questions' letter / GRAS) and China (CSAR), enabling commercial ingredient sales. Revenue-generating phase began in 2026 following commercial-scale production commencement.
  2. Technical and Regulatory Services: All G supports partners and customers with regulatory documentation, clinical trial data, claims dossiers, ingredient data, and technical expertise across global markets including dietary supplement, infant formula, and personal care. This supports customer product development and market entry.

Go-to-market motion3 records

Distribution channels3 records

Marketing channels4 records

All G product offering

Product offering

Core offering

All G develops and supplies high-purity bioactive milk proteins—including LFX™ bovine lactoferrin, human lactoferrin, micellar caseins, and human milk proteins—manufactured via precision fermentation of food-grade yeast. These protein ingredients are sold B2B to global manufacturers of infant formula, dietary supplements, functional foods/beverages, and personal care products, with bundled technical, regulatory, and clinical support. Commercial-scale production commenced in 2026 through a joint venture with Armor Protéines (Savencia Group).

Product overview

All G is an Australian biotechnology company that develops high-value human and bovine milk proteins through precision fermentation. The core product portfolio includes LFX™ Bovine Lactoferrin as the lead commercial product, along with Human Lactoferrin, Micellar Caseins, and Human Milk Proteins. The company also produced Love BUDS Burgers as its first consumer product. All products are produced using precision fermentation technology where microbes are programmed with DNA instructions and grown in fermentation tanks to produce bio-identical proteins. The product pipeline targets applications across infant formula, dietary supplements, personal care, and functional foods.

Differentiator

Problem solved

Functional benefit

Brands

  • LFX™: Precision-fermented bovine lactoferrin ingredient with >95% purity, bio-equivalent to animal-based lactoferrin.

Products and services

  • LFX™ Bovine Lactoferrin Precision-fermented bovine lactoferrin ingredient produced via microbial fermentation of food-grade yeast, offering >95% purity, bio-equivalent activity to animal-based lactoferrin, higher iron-binding capacity, and higher antioxidant activity. Designed for use in functional foods, beverages, dietary supplements, and personal care formulations by global manufacturers.
  • Human Lactoferrin Precision-fermented human lactoferrin protein produced via microbial fermentation. Adapted specifically to human biology, binding and delivering iron with high bioavailability. Naturally occurring in saliva, tears, and protective mucosal fluids. Designed for infant formula, dietary supplements, and advanced nutrition applications.
  • Micellar Caseins Precision-fermented micellar casein proteins that self-assemble into microscopic spheres with calcium and phosphate, mimicking the natural micellar structure found in milk. All G has filed patents covering stable casein micelle production from single casein protein types. Designed for infant formula and nutritional applications.
  • Human Milk Proteins Precision-fermented human milk proteins including human casein micelles and other breast milk proteins for infant formula and nutritional applications, developed to more closely align with the composition and function of human breast milk. Includes patented infant formulations containing five major human breast milk proteins.
  • Love BUDS Burgers Plant-based burger product developed using precision fermentation technology, launched as All G's first commercial product in Australian supermarkets.

Quantifiable outcome

  • Lactoferrin supplementation was associated with reduced systemic inflammation, improvements in immune function, and a lower incidence of respiratory tract infections in infants and children (meta-analysis of clinical trials)
  • +4 more outcomes

Companies that use All G

Customer profile

Named customers4 records

Segments4 records

Ideal customer profiles4 records

All G technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature6 records

All G partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core.

  • Armor Protéines (Savencia Group)coreStrategic or Co-development Partner · 18 December 2025All G formed a strategic joint venture with French lactoferrin producer Armor Protéines (owned by dairy major Savencia) to produce and commercialize bovine lactoferrin and human milk proteins at global scale. The JV combines All G's precision fermentation technology with Armor Protéines' established manufacturing infrastructure, supporting All G's first product launch of recombinant lactoferrin in 2026.
  • Doehler VenturescoreStrategic or Co-development Partner · 1 January 2022All G partnered with Doehler Ventures to establish a dedicated pilot facility in Germany supporting scale-up of precision fermentation production. Doehler Ventures also participated as an investor in All G's $10M convertible note fundraise in December 2025.
  • University of SydneycoreTechnology or Integration · 6 September 2021All G partnered with the University of Sydney for research collaboration as part of its founding strategy in 2021. The partnership supports the development of alternative proteins through academic research and expertise.
  • University of Queensland (FaBA)coreTechnology or IntegrationAll G is scaling up lactoferrin production through partnerships with the University of Queensland's FaBA (Food and Beverage Accelerator), which supports advanced food and biotechnology manufacturing capabilities.

Scale indicators6 records

Recent moves7 records

Expansion highlights6 records

All G competitors and assessment

Company assessment

Direct peers

  • Helaina: US-based precision fermentation company developing recombinant human lactoferrin and other bioactive proteins for infant formula and supplements — the closest direct competitor to All G's LFX™ product line.
  • Perfect Day: US precision fermentation leader producing animal-free whey protein for dairy applications; a broad platform competitor using similar microbial fermentation technology targeting B2B food and nutrition customers.
  • Remilk: Israel-based precision fermentation company producing animal-free whey and casein proteins for dairy and infant nutrition — directly comparable technology platform and end-markets to All G.
  • TurtleTree: Singapore/US precision fermentation company producing recombinant lactoferrin and other milk proteins using similar microbial host technology — direct overlap with All G's lactoferrin focus.
  • Imagindairy: Israel-based precision fermentation startup producing animal-free casein and whey proteins for dairy alternatives, applying analogous fermentation approaches for B2B dairy ingredient customers.
  • Those Vegan Cowboys: Belgium-based precision fermentation company producing animal-free casein proteins for cheese applications — comparable microbial fermentation platform targeting dairy protein markets.
  • Formo: Germany-based precision fermentation company producing animal-free cheese proteins using microbial fermentation — comparable technology and European market overlap with All G's German pilot facility via Doehler.

Emerging players

  • Vivici: Netherlands-based precision fermentation startup backed by DSM-Firmenich developing animal-free dairy proteins including lactoferrin — emerging competitor with corporate backing targeting overlapping B2B ingredient customers.
  • Bon Vivant: France-based precision fermentation company producing animal-free whey proteins for dairy applications — emerging competitor with overlap in European precision-fermented dairy protein markets.

Others

  • Armor Protéines (Savencia): French lactoferrin producer and All G's JV partner under Savencia Group — comparable as the leading animal-derived lactoferrin incumbent, with JV relationship creating both partnership and competitive dynamics for All G.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

All G social profiles

Digital presence

All G compliance and trust

Trust signal

Compliance4 records

All G financial estimates

Financial estimate

Revenue estimate

Valuation estimate

All G leadership team

Management profile

Number of profiles

Profiles6 records

All G subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

All G funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors13 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

All G M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about All G

What does All G do?

All G develops and supplies high-purity bioactive milk proteins—including LFX™ bovine lactoferrin, human lactoferrin, micellar caseins, and human milk proteins—manufactured via precision fermentation of food-grade yeast. These protein ingredients are sold B2B to global manufacturers of infant formula, dietary supplements, functional foods/beverages, and personal care products, with bundled technical, regulatory, and clinical support. Commercial-scale production commenced in 2026 through a joint venture with Armor Protéines (Savencia Group).

Is All G a public or private company?

All G is a private company. It is classified as venture growth investor backed and is currently operating.

When was All G founded?

All G was founded in 2021. It employs 11 to 50 people.

Where is All G based?

All G is headquartered in Sydney, Australia, in the Oceania region.

How does All G make money?

Two revenue lines are on record. Ingredient Sales — Lactoferrin and Milk Proteins are the primary driver. The others are technical and Regulatory Services.

Who are All G's main competitors?

Direct peers on record are Helaina, Perfect Day, Remilk, TurtleTree, Imagindairy, Those Vegan Cowboys and Formo. Emerging players are Vivici and Bon Vivant. Armor Protéines (Savencia) is listed as an others.

Does All G have an API?

No public API is recorded for All G.

What industry is All G in?

All G's product category is Precision Fermentation Protein Ingredients. Its primary akta.pro industry code is AFAHAJAJ, Precision-Fermentation Dairy Analogues Processing (Animal-Free Whey/Casein Products), with a secondary code of AFAKAKAF, Whey, Casein & Milk Protein Ingredient Manufacturing. Its NAICS code is 3115 and its SIC code is 2020.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
vegconomistAll G Adds Malaysian Life Sciences Investor Xeraya Capital to Pre-Series B RoundAustralian precision fermentation company All G has added Malaysian life sciences investor Xeraya Capital to its pre-Series B convertible note round. This investment secures a strategic pathway for All G to expand into Southeast Asian nutrition and infant formula markets, leveraging Xeraya's regional connections. The deal follows previous funding and commercial milestones, including US sales and regulatory approval in China.GreenqueenAll G Gets Funding from Malaysian Govt-Owned Fund for Animal-Free Dairy ProteinsMalaysian sovereign wealth fund Xeraya Capital has invested in Australian precision fermentation startup All G, joining its pre-Series B funding round. This investment supports All G's commercialization of animal-free dairy proteins and facilitates its expansion into Southeast Asian markets. The company continues to raise capital for a Series B round while developing human-identical milk proteins.AgFunderNewsAll G makes US debut with low-iron lactoferrin made via precision fermentationAustralian startup All G has launched its LFX apo-lactoferrin product in the US market, producing bovine-equivalent lactoferrin via precision fermentation with less than 5% iron saturation, compared to the industry standard of around 20%. The company has achieved positive unit economics at 60,000-liter scale and is producing multiple metric tons per year through a contract manufacturer in China. All G has secured FDA GRAS 'no questions' letter status and recently formed a joint venture with French dairy ingredients expert Armor Protéines to expand distribution in infant formula, adult nutrition, and supplements.foodnavigator-usa.comThe rise and rise of precision-fermented lactoferrinPrecision fermentation technology is enabling the scalable, animal-free production of lactoferrin—a protein traditionally extracted from cow's milk at high cost—as multiple companies race to commercialize both bovine and human forms. Key players including Turtle Tree, Vivici, All G, and Nestlé have secured regulatory approvals and strategic partnerships, with the global lactoferrin market projected to reach $810.11 million by 2034. Emerging applications span infant formula, women's health, and sports nutrition, supported by a €12.5 million European Innovation Council grant awarded to Vivici in June 2026.Personal Care InsightsIn-cosmetics Global 2026: All G delivers precision-fermented lactoferrin for sustainable efficacyAll G showcased its precision-fermented lactoferrin ingredient at the In-cosmetics Global 2026 trade show, positioning it as an animal-free, sustainable alternative to conventional lactoferrin. The company highlighted the ingredient's superior bioactivity, bioavailability, and clinical evidence supporting its efficacy, along with a stable, cost-effective supply chain free from animal products. The ingredient is designed to offer simplicity, efficacy, and multifunctionality for personal care formulations.GreenqueenExclusive: All G Earns FDA Approval to Sell Cow-Free Lactoferrin Protein in USAustralian startup All G has received a 'no questions' letter from the US FDA for its precision-fermented lactoferrin ingredient (LFX), which it will begin selling in the US market within months after obtaining GRAS status. The company uses microbial fermentation to produce cow-free lactoferrin offering purity above 99.5% and higher bioactivity than animal-based versions, with pricing aligned to current market rates. All G is scaling up production through partnerships with the University of Queensland's FaBA and a joint venture with Armor Protéines (owned by dairy major Savencia), targeting functional foods, dietary supplements, and eventually the infant nutrition market.TipranksAll G Gains FDA Regulatory Milestone for Precision-Fermented LactoferrinAll G has received a U.S. Food and Drug Administration "no questions" letter regarding the safety of its precision-fermented lactoferrin ingredient LFX™, providing regulatory validation for use across food, beverages, and dietary supplements. The milestone delivers external validation for the ingredient's more than 99.5% purity and high bioactivity, positioning the company to target early life nutrition markets where lactoferrin is supply-constrained. The development represents All G's transition from R&D focus toward a commercial phase, potentially enabling partnerships with food, beverage, and supplement manufacturers in higher-value specialty protein markets.FoodinstituteStartups Race to Recreate Human Milk Proteins for Infant NutritionA growing number of biotech startups across the U.S., Europe, Australia, and China are using precision fermentation technology to produce human milk proteins such as lactoferrin and beta-casein for infant formula, nutritional supplements, and functional nutrition products. The precision fermentation ingredients market is currently valued at $5.02 billion and projected to reach $35 billion by 2030 with a 48.6% CAGR, according to Markets and Markets. Key companies in the space include Australian startup All G, Chinese biotech firm Guoke Xinglian (which recently raised $14.6 million in Series A funding), Helaina, and TurtleTree, though scientists caution that replicating the full biological complexity of human milk—including glycosylation patterns and the complete milk matrix—remains a significant technical challenge.FoodinstituteStartups Race to Recreate Human Milk Proteins for Infant NutritionBiotech startups across the U.S., Europe, Australia, and China are using precision fermentation technology to recreate key components of human breast milk, including lactoferrin and beta-casein, for infant formula and nutritional products. The precision fermentation ingredients market is currently valued at $5.02 billion and projected to reach $35 billion by 2030 with a 48.6% CAGR, driven by demand for sustainable, animal-free ingredients. Companies including All G, Guoke Xinglian, Helaina, and TurtleTree are developing these proteins, though scientists caution that replicating the full biological complexity of human milk—including dynamic glycosylation patterns and the complete milk matrix—remains a significant technical challenge.